IQVIA (NYSE:IQV) (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.
IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement. Its products and services are designed to help customers make decisions across the pharmaceutical product life cycle, from research and development through commercialization.
The company serves customers in numerous countries across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. IQVIA was formed through the 2016 merger of IMS Health and Quintiles, combining healthcare information and analytics capabilities with contract research and related services. The company adopted the IQVIA name in 2017.
IQVIA is led by Chairman and Chief Executive Officer Ari Bousbib, who has served in that role since the company’s formation. Its customers include pharmaceutical and biotechnology companies, healthcare providers, government organizations and other participants in the global healthcare sector.
